EatDrama
Entertainment

STAT Plus: FDA staff reiterate concerns about Replimune skin cancer treatment

STAT Plus: FDA staff reiterate concerns about Replimune skin cancer treatment

An advisory committee is set to review the treatment, called RP1, that has been at the center of heated debate over agency standards.

Open original source

Featured Creators

Creators building their communities through the SpiderTaz Creator Program.

View creators →